Introduction
Experimental data suggest that oxidative stress and inflammation play a role in the pathogenesis of heart failure (HF). Although sparse, available evidence in humans also indicates that oxidative stress and inflammation may contribute to the development of HF. 1, 2 However, although the more severe left ventricular dysfunction correlates with the more pronounced increase in plasma levels of oxidative and inflammatory biomarkers, the cause and effect relationship could not be established. 3 In addition, several randomised trials have failed to demonstrate the clinical benefit of unselective anti-inflammatory and antioxidant therapies in patients with HF. More recently, progress has been achieved with novel therapies directed at key oxidative/inflammatory mediators supposedly involved in HF pathogenesis. However, these novel agents have demonstrated equivocal results in clinical trials. Hence, the clinical significance of interventions targeting oxidative/inflammatory stress in HF remains unresolved.
The review by Aimo et al. 4 in this issue of the journal summarises the pathophysiology and the current knowledge on pharmacological treatment of oxidative stress and inflammation in HF, stressing implications relevant for clinical practice.
Oxidative stress and inflammation in heart failure: pathophysiology and therapeutic strategies Aimo and colleagues 4 provide a comprehensive overview of the role of oxidative stress and inflammation in the development of either heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF). 5 The authors indicate that, in HFrEF, mitochondrial dysfunction in the myocardium, driven by increased neurohormonal stimulation, may be the most important source of oxidative stress. 6, 7 In addition, the upregulation of oxidative enzymes (e.g. nicotinamide adenine dinucleotide phosphate oxidase) and uncoupling of nitric oxide synthase may contribute to the increased oxidative burden. 3 The uncontrolled production of reactive oxygen species (ROS)/reactive nitrogen species (RNS) may cause cellular damage and apoptosis, and contribute to maladaptive remodelling, systolic dysfunction and the occurrence of arrhythmias in HFrEF. 3 Contrary to HFrEF, in patients with HFpEF associated comorbidities (e.g. overweight/obesity, diabetes, chronic obstructive pulmonary disease and hypertension) may be key drivers of chronic systemic inflammation and oxidative stress. It is suggested that exposure to chronic oxidative/ inflammatory stress may be the cause of microvascular endothelial dysfunction in the myocardium, which promotes the development of cardiomyocyte hypertrophy and interstitial fibrosis in HFpEF. 1 The review also provides a clinical perspective of oxidative/inflammatory stress with the summary of clinical trials, which have assessed unselective antiinflammatory/antioxidative interventions in HF. As demonstrated by the HOPE and GISSI-prevenzione trials, vitamin E failed to provide a beneficial effect to either the prevention or treatment of HF. 8, 9 Notably, it increased the risk of hospitalisation or death in patients with left ventricular ejection fraction (LVEF) less than 50%. It was assumed that high-dosage vitamin E interfered with the metabolism of other HF medications, thus outweighing the benefits of its antioxidant effects. Furthermore, limited activity against other putative oxidants (e.g. superoxide, peroxynitrite and hypochlorous acid) might have attenuated the positive effects of vitamin E. Likewise, in a clinical trial, vitamin C had no effect on the prevention of incident HF and data are lacking on its use for the treatment of HF. 10 Hyperuricaemia is associated with an increased risk of new-onset HF in patients with hypertension or coronary artery disease. Also, higher uric acid levels confer a greater risk of adverse outcomes in patients with established HF. Despite these associations, the xantine oxidase inhibitor, allopurinol, failed to improve clinical status, quality of life, or LVEF in patients with HF. 11 Furthermore, a more pronounced deficiency of coenzyme Q10 was correlated with the greater severity of HF. Hence, supplementation of coenzyme Q10 was considered as a possible therapeutic strategy for HF. However, evidence is conflicting, as meta-analyses of clinical trials demonstrated diverging results on the effects of coenzyme Q10 supplementation on symptoms and outcomes in patients with HF.
Considering the use of the more targeted novel antiinflammatory therapies, the tumour necrosis factor alpha (TNFa) inhibitor, etanercept, showed no improvement in mortality or hospitalisation in patients with HF and LVEF of 30% or less. Another TNFa antagonist, infliximab, did not improve the clinical condition of patients with moderate to severe chronic HF, and it even worsened patient prognosis when given in high doses. These results suggest that TNFa may have a protective role to a certain extent, and that its pharmacological inhibition may be harmful in HF. Although underpowered for outcomes, a trial with the interleukin 1 antagonist, anakinra, in recently decompensated HF patients, showed an improvement in peak oxygen consumption, but without influencing the risk of death or HF hospitalisation.
The review by Aimo et al. also provides several explanations of why antioxidant treatments were effective in vitro and in animal models of HF, but failed to improve outcomes in human studies of HF. 4 Concentrations of antioxidant agents used in in vitro studies may have been much higher compared with those that can be obtained after oral ingestion in humans. 12, 13 Furthermore, genetically mediated differences in the resorption and metabolism of certain vitamins can significantly affect their bioavailability after oral intake. Also, most studies assessed major cardiovascular events (MACE) as primary endpoints. As MACE are predominantly driven by atherosclerotic plaque rupture, subtle improvements in endothelial function or lipid peroxidation with antioxidants may be insufficient to prevent such an event. Furthermore, oxidative mediators strongly implicated in vascular damage (hydrogen peroxide and hypochlorous acid) evade scavenging and their harmful effects remain unopposed despite vitamin supplementation. 14 Also, the majority of trials included only high-risk patients, with advanced vascular disease and ischaemic HF, 15 often treated with acetylsalicylic acid, in whom the added benefits of antioxidant supplementation were less likely to be perceived. Notably, the effects of antioxidant medications in patients with non-ischaemic HF are currently less well understood.
The review by Aimo et al. can be commended for the comprehensiveness in describing oxidative and inflammatory pathways implicated in HF development, as well as earlier studies of unselective anti-inflammatory/ antioxidant treatments. 4 However, one limitation has to be pointed out concerning the lack of a detailed discussion on the contemporary trials and novel/emerging approaches to anti-inflammatory/antioxidant treatments in HF.
Future perspective
Although earlier trials failed to demonstrate better outcomes with antioxidant and anti-inflammatory drugs in HF patients, inflammation and oxidative stress never ceased to be the focus of intensive research. This research explores the more targeted treatments directed against specific components of the inflammatory/ oxidative pathways.
The CANTOS trial, one of the largest newer studies in this field, demonstrated that treatment with a monoclonal antibody directed against interleukin-1b (canakinumab) can significantly lower the rate of cardiovascular events in patients with recent myocardial infarction and high C-reactive protein levels, already receiving statin therapy. 16 The subanalysis of this trial suggested a trend towards a dose-dependent reduction in HF hospitalisation and the composite endpoint of HF hospitalisation or HF-related mortality with canakinumab compared with placebo. 17 A randomised trial of the novel peptide (elamipretide), which reduces the mitochondrial production of ROS, demonstrated favourable changes in left ventricular volumes in patients with HF receiving this drug. 18 Yet another anti-inflammatory drug, specifically blocking the effects of interleukin-1 (anakinra), was evaluated in a cohort of clinically stable HF patients with near-normal left ventricular dimensions and function. Although anakinra failed to show significant effects on left ventricular volumes or LVEF, the drug led to a numerically lower incidence of HF events compared with placebo. 19 Based on this experience, the ongoing trials of novel agents are under way. These include assessing the effects of subcutaneous elamipretide on left ventricular function in stable HFpEF (NCT02814097), and as well as various other measures of left ventricular contractile function in HFrEF (NCT02788747). In addition, the effects of anakinra are being evaluated in a trial of HFpEF patients (Diastolic Heart Failure Anakinra Response Trial 2, D-HART2). 20 Besides pharmacological treatment, nonpharmacological interventions may also prove beneficial for decreasing the oxidative and inflammatory burden and improving outcomes in HF. High intensity inspiratory muscle training was shown to enhance functional status and to decrease inflammation slightly in chronic HF. 21 Likewise, walking exercise was also shown to decrease the mediators of inflammation and oxidative stress and to improve functional capacity and quality of life in HF patients. 22 
Conclusions
The use of antioxidants/anti-inflammatory agents in the treatment of HF yielded neutral or inconclusive results. A possible explanation is that unselective inflammatory suppression may be harmful in HF, because it also interferes with protective mechanisms, such as cellular signalling pathways, immune defence and mitochondrial energy production. 23 Consequently, interventions directed to the more specific and balanced inhibition of oxidative/inflammatory mechanisms in HF should be investigated. 24 Recent trials of the more selective agents produced promising results, and ongoing research along the same line is needed. In addition, strategies aimed at preventing ROS/RNS production or stimulating endogenous antioxidant systems should be also taken into consideration. The best is yet to come with further research into potential anti-inflammatory/ antioxidant interventions targeting specific HF aetiologies or relevant intracellular compartments (e.g. mitochondria).
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